A Phase IV, Single-Centre, Non-Randomised, Controlled, Open-Label Study to Assess the Use of Growth Hormone (GH) Replacement Therapy (NutropinAq) During Transition in GH Deficient Survivors of Childhood Cancer to Optimise Somatic Growth & Well-Being
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- 17 Dec 2015 New trial record